| Literature DB >> 33945108 |
P Luyten1,2, S Heuts3, E Cheriex1, J R Olsthoorn4, H J G M Crijns1,5, B Winkens6, J W Roos-Hesselink7, P Sardari Nia4,5, S Schalla1,5,8.
Abstract
INTRODUCTION: In patients with mitral annular disjunction (MAD), it can be difficult to assess the severity of mitral regurgitation (MR), as they present with a prolapsing volume (i.e. volume resulting from mitral valve prolapse, blood volume shift) rather than a regurgitant jet. The influence of the mitral prolapsing volume (MPV) on cardiac dimensions is unknown. We hypothesised that the severity of MR is underestimated in these patients. Our aim was to measure MPV and to investigate its influence on cardiac dimensions in patients with MAD.Entities:
Keywords: Echocardiography; Mitral annular disjunction; Mitral regurgitation; Prolapsing volume
Year: 2021 PMID: 33945108 PMCID: PMC8881558 DOI: 10.1007/s12471-021-01575-6
Source DB: PubMed Journal: Neth Heart J ISSN: 1568-5888 Impact factor: 2.380
Fig. 1Schematic representation of mitral annular disjunction, showing displacement of the mitral hinge point, away from the ventricular myocardium towards the left atrium. The prolapse results in a volume shift without an effective regurgitant jet
Fig. 2a–f Echocardiographic evaluation and quantification of mitral prolapsing volume. a–c Four-chamber view demonstrating a mitral annular disjunction, b measurements of atrial dimensions up to the level of the annulus (blue) and the mitral valve (green), resulting in c the prolapse surface. d–f Two-chamber view in the same patient demonstrating d mitral annular disjunction, e measurements and f prolapse surface
Characteristics of mitral annular disjunction patients
| Baseline characteristics | |
|---|---|
| Age (years) | 64 (17–90) |
| Gender (male) | 64 (49%) |
| BSA (m | 1.80 (1.67–1.95) |
| Atrial fibrillation | 47 (36%) |
| Coronary artery disease | 20 (15%) |
| Myocardial infarction | 10 (8%) |
| I | 50 (38%) |
| II | 61 (47%) |
| III | 20 (15%) |
| IV | 0 |
| LVEF% | 62 (57–66) |
| LVESD (mm) | 35 (31–39) |
| LVEDD (mm) | 53 ± 7 |
| TR jet velocity (m/s) | 2.4 (2.1–2.8) |
| Mild | 49 (37%) |
| Moderate | 34 (26%) |
| Severe | 48 (37%) |
| 104 (77–143) | |
| 12 (7–17) | |
Data are number and percentage (%), median (range) or mean ± standard deviation
BSA body surface area, NYHA New York Heart Association, LVEF left ventricular ejection fraction, LVESD left ventricular end-systolic diameter, LVEDD left ventricular end-diastolic diameter, TR tricuspid regurgitation, MR mitral regurgitation
Univariable and multivariable regression analysis for left ventricular end-diastolic diameter (LVEDD), left ventricular end-systolic diameter (LVESD) and left atrial volume
| Variable | B | β | CI | |||
|---|---|---|---|---|---|---|
| Age | 0.21 | 0.02 | −0.04 | −0.10 | −0.09–0.02 | 0.23 |
| BSA | 0.52 | < 0.01 | 9.86 | 0.34 | 4.07–15.64 | < 0.01 |
| Gender | 0.34 | < 0.01 | −0.96 | −0.08 | −3.27–1.36 | 0.42 |
| Mitral prolapsing volume | 0.38 | < 0.01 | 0.06 | 0.18 | 0.01–0.26 | 0.04 |
| MR gradation | 0.23 | 0.01 | 0.57 | 0.23 | 0.61–2.88 | < 0.01 |
| Atrial fibrillation | 0.11 | 0.22 | ||||
| Coronary artery disease | 0.10 | 0.24 | ||||
| Age | 0.22 | 0.12 | −0.25 | −0.08 | −0.08–0.03 | 0.37 |
| BSA | 0.41 | < 0.01 | 6.45 | 0.25 | 0.87–12.01 | 0.02 |
| Gender | 0.30 | < 0.01 | −0.76 | −0.07 | −2.99–1.50 | 0.50 |
| Mitral prolapsing volume | 0.35 | < 0.01 | 0.135 | 0.20 | 0.01–0.26 | 0.03 |
| MR gradation | 0.09 | 0.31 | ||||
| Age | 0.09 | 0.32 | ||||
| BSA | 0.38 | < 0.01 | 54.42 | 0.25 | 18.73–90.12 | < 0.01 |
| Gender | 0.25 | < 0.01 | −0.95 | −0.10 | −15.74–13.85 | 0.90 |
| Mitral prolapsing volume | 0.29 | < 0.01 | 0.86 | 0.16 | 0.05–1.67 | 0.04 |
| MR gradation | 0.45 | < 0.01 | 23.42 | 0.43 | 16.14–30.70 | < 0.01 |
| Atrial fibrillation | 0.44 | < 0.01 | −31.20 | −0.32 | −44.22–−18.17 | < 0.01 |
| Coronary artery disease | 0.06 | 0.51 | ||||
BSA body surface area, CI confidence interval, MR mitral regurgitation
Characteristics for prolapsing volumes > 15 ml
| Large prolapsing volume (> 15 ml) | Degenerative group | ||
|---|---|---|---|
| Age (years) | 62 (47–75) | 67 (54–77) | 0.204 |
| Gender | 22 (71%) | 52 (50%) | 0.041 |
| BSA | 1.9 (1.8–2.1) | 1.9 (1.7–2.0) | 0.179 |
| Coronary artery disease | 2 (7%) | 14 (13%) | 0.525 |
| Atrial fibrillation | 11 (36%) | 38 (36%) | 1.000 |
| 0.302 | |||
| I | 12 (38%) | 50 (48%) | |
| II | 9 (29%) | 42 (40%) | |
| III | 10 (33%) | 13 (12%) | |
| 0.640 | |||
| Mild | 12 (38%) | 46 (44%) | |
| Moderate | 9 (29%) | 22 (21%) | |
| Severe | 10 (33%) | 37 (35%) | |
| Mitral prolapsing volume | 22 (17–26) | 0 | |
| Left atrial volume | 105 (86–159) | 101 (66–123) | 0.040 |
| LVEDD | 56 ± 6 | 51 ± 6 | < 0.001 |
| LVESD | 38 (34–41) | 34 (31–39) | < 0.01 |
| LVEF | 62 (57–65) | 62 (55–65) | 0.913 |
Data are number and percentage (%), median (range) or mean ± standard deviation
BSA body surface area, NYHA New York Heart Association classification for dyspnoea, MR mitral regurgitation, LVEDD left ventricular end-diastolic diameter, LVESD left ventricular end-systolic diameter, LVEF left ventricular ejection fraction